nodes	percent_of_prediction	percent_of_DWPC	metapath
Nabumetone—osteoarthritis—Prednisone—multiple sclerosis	0.332	0.5	CpDpCtD
Nabumetone—osteoarthritis—Methylprednisolone—multiple sclerosis	0.332	0.5	CpDpCtD
Nabumetone—PTGS2—Triamcinolone—multiple sclerosis	0.081	0.424	CbGbCtD
Nabumetone—PTGS2—Betamethasone—multiple sclerosis	0.0695	0.364	CbGbCtD
Nabumetone—PTGS2—Dexamethasone—multiple sclerosis	0.0404	0.212	CbGbCtD
Nabumetone—MPO—IL23-mediated signaling events—IL23A—multiple sclerosis	0.00193	0.0658	CbGpPWpGaD
Nabumetone—PTGS2—S1P1 pathway—S1PR1—multiple sclerosis	0.00101	0.0343	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—STAT4—multiple sclerosis	0.000918	0.0313	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL17A—multiple sclerosis	0.000905	0.0308	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL12B—multiple sclerosis	0.000841	0.0287	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTPRK—multiple sclerosis	0.000766	0.0261	CbGpPWpGaD
Nabumetone—PTGS2—Fluocinonide—Methylprednisolone—multiple sclerosis	0.000552	0.159	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Dexamethasone—multiple sclerosis	0.000543	0.156	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Betamethasone—multiple sclerosis	0.000543	0.156	CbGdCrCtD
Nabumetone—PTGS2—Fluocinonide—Triamcinolone—multiple sclerosis	0.000531	0.153	CbGdCrCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TBX21—multiple sclerosis	0.000493	0.0168	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—CCL5—multiple sclerosis	0.000477	0.0163	CbGpPWpGaD
Nabumetone—PTGS1—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.000445	0.0152	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000435	0.0148	CbGpPWpGaD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000435	0.0148	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—CCL2—multiple sclerosis	0.000425	0.0145	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—APOE—multiple sclerosis	0.000391	0.0133	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—TYK2—multiple sclerosis	0.000386	0.0132	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.00038	0.013	CbGpPWpGaD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.00038	0.013	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—IL4—multiple sclerosis	0.000376	0.0128	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—ICAM1—multiple sclerosis	0.000368	0.0125	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CBLB—multiple sclerosis	0.000362	0.0123	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IFNG—multiple sclerosis	0.000362	0.0123	CbGpPWpGaD
Nabumetone—PTGS2—Prostaglandin Synthesis and Regulation—PTGER4—multiple sclerosis	0.000353	0.012	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—CD4—multiple sclerosis	0.000349	0.0119	CbGpPWpGaD
Nabumetone—PTGS2—Fluticasone Propionate—Methylprednisolone—multiple sclerosis	0.000333	0.0958	CbGdCrCtD
Nabumetone—MPO—Vitamin B12 Metabolism—CCL2—multiple sclerosis	0.000329	0.0112	CbGpPWpGaD
Nabumetone—PTGS2—Fluticasone Propionate—Betamethasone—multiple sclerosis	0.000328	0.0942	CbGdCrCtD
Nabumetone—PTGS2—Fluticasone Propionate—Dexamethasone—multiple sclerosis	0.000328	0.0942	CbGdCrCtD
Nabumetone—MPO—IL23-mediated signaling events—IL1B—multiple sclerosis	0.000323	0.011	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL2—multiple sclerosis	0.000321	0.011	CbGpPWpGaD
Nabumetone—PTGS2—Fluticasone Propionate—Triamcinolone—multiple sclerosis	0.00032	0.0921	CbGdCrCtD
Nabumetone—MPO—Vitamin B12 Metabolism—ALB—multiple sclerosis	0.000307	0.0104	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—ICAM1—multiple sclerosis	0.000299	0.0102	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—FOXP3—multiple sclerosis	0.000293	0.01	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—IFNG—multiple sclerosis	0.00028	0.00953	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—STAT3—multiple sclerosis	0.00027	0.00921	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—CCL2—multiple sclerosis	0.000268	0.00912	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—IL1B—multiple sclerosis	0.000249	0.0085	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—ALB—multiple sclerosis	0.000249	0.0085	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—CD40LG—multiple sclerosis	0.000243	0.00827	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000241	0.00822	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000241	0.00822	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000238	0.00812	CbGpPWpGaD
Nabumetone—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000238	0.00812	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—ICAM1—multiple sclerosis	0.000238	0.0081	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL4—multiple sclerosis	0.000236	0.00805	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—TNF—multiple sclerosis	0.000234	0.00798	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP27B1—multiple sclerosis	0.000231	0.00788	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—CYP24A1—multiple sclerosis	0.000231	0.00788	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—IFNG—multiple sclerosis	0.000228	0.00776	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2RA—multiple sclerosis	0.000216	0.00737	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—CCL2—multiple sclerosis	0.000213	0.00725	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MBP—multiple sclerosis	0.000211	0.00719	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000207	0.00705	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—IL1B—multiple sclerosis	0.000203	0.00692	CbGpPWpGaD
Nabumetone—MPO—Folate Metabolism—IL2—multiple sclerosis	0.000202	0.00689	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CTLA4—multiple sclerosis	0.000202	0.00688	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—ALB—multiple sclerosis	0.000198	0.00675	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000196	0.00667	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000196	0.00667	CbGpPWpGaD
Nabumetone—MPO—IL23-mediated signaling events—IL6—multiple sclerosis	0.000189	0.00644	CbGpPWpGaD
Nabumetone—MPO—C-MYB transcription factor network—CD4—multiple sclerosis	0.000181	0.00618	CbGpPWpGaD
Nabumetone—MPO—Vitamin B12 Metabolism—TNF—multiple sclerosis	0.000181	0.00617	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IFNG—multiple sclerosis	0.000181	0.00616	CbGpPWpGaD
Nabumetone—PTGS1—Overview of nanoparticle effects—TNF—multiple sclerosis	0.000163	0.00556	CbGpPWpGaD
Nabumetone—MPO—Selenium Micronutrient Network—IL1B—multiple sclerosis	0.000161	0.0055	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—AQP4—multiple sclerosis	0.00016	0.00545	CbGpPWpGaD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—CD40LG—multiple sclerosis	0.000157	0.00535	CbGpPWpGaD
Nabumetone—Haemorrhage—Prednisone—multiple sclerosis	0.000153	0.00136	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL4—multiple sclerosis	0.000153	0.00521	CbGpPWpGaD
Nabumetone—Malaise—Triamcinolone—multiple sclerosis	0.000152	0.00135	CcSEcCtD
Nabumetone—Malaise—Methylprednisolone—multiple sclerosis	0.000152	0.00134	CcSEcCtD
Nabumetone—Vertigo—Triamcinolone—multiple sclerosis	0.000152	0.00134	CcSEcCtD
Nabumetone—Syncope—Triamcinolone—multiple sclerosis	0.000152	0.00134	CcSEcCtD
Nabumetone—Vertigo—Methylprednisolone—multiple sclerosis	0.000152	0.00134	CcSEcCtD
Nabumetone—Syncope—Methylprednisolone—multiple sclerosis	0.000151	0.00134	CcSEcCtD
Nabumetone—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000151	0.00133	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisolone—multiple sclerosis	0.00015	0.00133	CcSEcCtD
Nabumetone—Oedema—Prednisolone—multiple sclerosis	0.00015	0.00133	CcSEcCtD
Nabumetone—Dysuria—Methotrexate—multiple sclerosis	0.00015	0.00132	CcSEcCtD
Nabumetone—Dizziness—Azathioprine—multiple sclerosis	0.00015	0.00132	CcSEcCtD
Nabumetone—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000149	0.00132	CcSEcCtD
Nabumetone—Loss of consciousness—Triamcinolone—multiple sclerosis	0.000149	0.00131	CcSEcCtD
Nabumetone—Loss of consciousness—Methylprednisolone—multiple sclerosis	0.000148	0.00131	CcSEcCtD
Nabumetone—Shock—Prednisolone—multiple sclerosis	0.000148	0.00131	CcSEcCtD
Nabumetone—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000148	0.0013	CcSEcCtD
Nabumetone—Cough—Triamcinolone—multiple sclerosis	0.000147	0.0013	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—TNF—multiple sclerosis	0.000147	0.00502	CbGpPWpGaD
Nabumetone—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000146	0.00129	CcSEcCtD
Nabumetone—MPO—Vitamin B12 Metabolism—IL6—multiple sclerosis	0.000146	0.00498	CbGpPWpGaD
Nabumetone—Hypertension—Triamcinolone—multiple sclerosis	0.000146	0.00129	CcSEcCtD
Nabumetone—Hypertension—Methylprednisolone—multiple sclerosis	0.000146	0.00129	CcSEcCtD
Nabumetone—Urticaria—Mitoxantrone—multiple sclerosis	0.000145	0.00128	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000145	0.00128	CcSEcCtD
Nabumetone—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000145	0.00128	CcSEcCtD
Nabumetone—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000145	0.00128	CcSEcCtD
Nabumetone—Vomiting—Azathioprine—multiple sclerosis	0.000144	0.00127	CcSEcCtD
Nabumetone—Pneumonia—Methotrexate—multiple sclerosis	0.000144	0.00127	CcSEcCtD
Nabumetone—Anxiety—Methylprednisolone—multiple sclerosis	0.000143	0.00127	CcSEcCtD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IFNG—multiple sclerosis	0.000143	0.00486	CbGpPWpGaD
Nabumetone—Rash—Azathioprine—multiple sclerosis	0.000143	0.00126	CcSEcCtD
Nabumetone—Dermatitis—Azathioprine—multiple sclerosis	0.000142	0.00126	CcSEcCtD
Nabumetone—Depression—Methotrexate—multiple sclerosis	0.000142	0.00126	CcSEcCtD
Nabumetone—Ill-defined disorder—Betamethasone—multiple sclerosis	0.000142	0.00126	CcSEcCtD
Nabumetone—Ill-defined disorder—Dexamethasone—multiple sclerosis	0.000142	0.00126	CcSEcCtD
Nabumetone—Discomfort—Triamcinolone—multiple sclerosis	0.000142	0.00126	CcSEcCtD
Nabumetone—Discomfort—Methylprednisolone—multiple sclerosis	0.000142	0.00125	CcSEcCtD
Nabumetone—Headache—Azathioprine—multiple sclerosis	0.000142	0.00125	CcSEcCtD
Nabumetone—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000142	0.00125	CcSEcCtD
Nabumetone—Dry mouth—Triamcinolone—multiple sclerosis	0.000141	0.00124	CcSEcCtD
Nabumetone—Renal failure—Methotrexate—multiple sclerosis	0.00014	0.00124	CcSEcCtD
Nabumetone—Angioedema—Betamethasone—multiple sclerosis	0.00014	0.00124	CcSEcCtD
Nabumetone—Angioedema—Dexamethasone—multiple sclerosis	0.00014	0.00124	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2RA—multiple sclerosis	0.00014	0.00477	CbGpPWpGaD
Nabumetone—Stomatitis—Methotrexate—multiple sclerosis	0.000139	0.00123	CcSEcCtD
Nabumetone—Confusional state—Methylprednisolone—multiple sclerosis	0.000139	0.00123	CcSEcCtD
Nabumetone—Malaise—Betamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Malaise—Dexamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Oedema—Triamcinolone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Vertigo—Betamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Vertigo—Dexamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Syncope—Betamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Syncope—Dexamethasone—multiple sclerosis	0.000138	0.00122	CcSEcCtD
Nabumetone—Arrhythmia—Prednisone—multiple sclerosis	0.000137	0.00121	CcSEcCtD
Nabumetone—Haematuria—Methotrexate—multiple sclerosis	0.000136	0.0012	CcSEcCtD
Nabumetone—PTGS2—S1P1 pathway—MAPK1—multiple sclerosis	0.000136	0.00464	CbGpPWpGaD
Nabumetone—Shock—Triamcinolone—multiple sclerosis	0.000136	0.0012	CcSEcCtD
Nabumetone—Insomnia—Prednisolone—multiple sclerosis	0.000136	0.0012	CcSEcCtD
Nabumetone—Alopecia—Prednisone—multiple sclerosis	0.000136	0.0012	CcSEcCtD
Nabumetone—Shock—Methylprednisolone—multiple sclerosis	0.000135	0.0012	CcSEcCtD
Nabumetone—Loss of consciousness—Dexamethasone—multiple sclerosis	0.000135	0.00119	CcSEcCtD
Nabumetone—Loss of consciousness—Betamethasone—multiple sclerosis	0.000135	0.00119	CcSEcCtD
Nabumetone—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000135	0.00119	CcSEcCtD
Nabumetone—Paraesthesia—Prednisolone—multiple sclerosis	0.000135	0.00119	CcSEcCtD
Nabumetone—Nausea—Azathioprine—multiple sclerosis	0.000134	0.00119	CcSEcCtD
Nabumetone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000133	0.00118	CcSEcCtD
Nabumetone—Agranulocytosis—Methotrexate—multiple sclerosis	0.000133	0.00118	CcSEcCtD
Nabumetone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000133	0.00118	CcSEcCtD
Nabumetone—Hypertension—Dexamethasone—multiple sclerosis	0.000132	0.00117	CcSEcCtD
Nabumetone—Hypertension—Betamethasone—multiple sclerosis	0.000132	0.00117	CcSEcCtD
Nabumetone—PTGS1—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000132	0.00449	CbGpPWpGaD
Nabumetone—Asthenia—Mitoxantrone—multiple sclerosis	0.000131	0.00116	CcSEcCtD
Nabumetone—MPO—C-MYB transcription factor network—MYC—multiple sclerosis	0.00013	0.00444	CbGpPWpGaD
Nabumetone—Anxiety—Dexamethasone—multiple sclerosis	0.00013	0.00115	CcSEcCtD
Nabumetone—Anxiety—Betamethasone—multiple sclerosis	0.00013	0.00115	CcSEcCtD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.00013	0.00443	CbGpPWpGaD
Nabumetone—PTGS2—Overview of nanoparticle effects—TNF—multiple sclerosis	0.00013	0.00442	CbGpPWpGaD
Nabumetone—Discomfort—Dexamethasone—multiple sclerosis	0.000129	0.00114	CcSEcCtD
Nabumetone—Discomfort—Betamethasone—multiple sclerosis	0.000129	0.00114	CcSEcCtD
Nabumetone—Haemoglobin—Methotrexate—multiple sclerosis	0.000129	0.00114	CcSEcCtD
Nabumetone—Haemorrhage—Methotrexate—multiple sclerosis	0.000128	0.00113	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000128	0.00436	CbGpPWpGaD
Nabumetone—PTGS2—Calcium signaling in the CD4+ TCR pathway—IL2—multiple sclerosis	0.000127	0.00432	CbGpPWpGaD
Nabumetone—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000125	0.00111	CcSEcCtD
Nabumetone—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000125	0.00111	CcSEcCtD
Nabumetone—Oedema—Betamethasone—multiple sclerosis	0.000125	0.00111	CcSEcCtD
Nabumetone—Oedema—Dexamethasone—multiple sclerosis	0.000125	0.00111	CcSEcCtD
Nabumetone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000125	0.00111	CcSEcCtD
Nabumetone—Insomnia—Triamcinolone—multiple sclerosis	0.000125	0.0011	CcSEcCtD
Nabumetone—Insomnia—Methylprednisolone—multiple sclerosis	0.000124	0.0011	CcSEcCtD
Nabumetone—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000124	0.00424	CbGpPWpGaD
Nabumetone—Ill-defined disorder—Prednisone—multiple sclerosis	0.000124	0.0011	CcSEcCtD
Nabumetone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000124	0.0011	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000124	0.00109	CcSEcCtD
Nabumetone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000124	0.00109	CcSEcCtD
Nabumetone—Visual impairment—Methotrexate—multiple sclerosis	0.000124	0.00109	CcSEcCtD
Nabumetone—Anaemia—Prednisone—multiple sclerosis	0.000123	0.00109	CcSEcCtD
Nabumetone—Shock—Dexamethasone—multiple sclerosis	0.000123	0.00109	CcSEcCtD
Nabumetone—Shock—Betamethasone—multiple sclerosis	0.000123	0.00109	CcSEcCtD
Nabumetone—Dyspnoea—Triamcinolone—multiple sclerosis	0.000123	0.00109	CcSEcCtD
Nabumetone—Agitation—Prednisone—multiple sclerosis	0.000123	0.00109	CcSEcCtD
Nabumetone—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000123	0.00108	CcSEcCtD
Nabumetone—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000123	0.00108	CcSEcCtD
Nabumetone—Angioedema—Prednisone—multiple sclerosis	0.000122	0.00108	CcSEcCtD
Nabumetone—Dyspepsia—Triamcinolone—multiple sclerosis	0.000121	0.00107	CcSEcCtD
Nabumetone—Erythema multiforme—Methotrexate—multiple sclerosis	0.000121	0.00107	CcSEcCtD
Nabumetone—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000121	0.00107	CcSEcCtD
Nabumetone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000121	0.00107	CcSEcCtD
Nabumetone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000121	0.00107	CcSEcCtD
Nabumetone—Malaise—Prednisone—multiple sclerosis	0.00012	0.00107	CcSEcCtD
Nabumetone—Vertigo—Prednisone—multiple sclerosis	0.00012	0.00106	CcSEcCtD
Nabumetone—Syncope—Prednisone—multiple sclerosis	0.00012	0.00106	CcSEcCtD
Nabumetone—Tinnitus—Methotrexate—multiple sclerosis	0.00012	0.00106	CcSEcCtD
Nabumetone—Anorexia—Dexamethasone—multiple sclerosis	0.000119	0.00106	CcSEcCtD
Nabumetone—Anorexia—Betamethasone—multiple sclerosis	0.000119	0.00106	CcSEcCtD
Nabumetone—Urticaria—Prednisolone—multiple sclerosis	0.000119	0.00105	CcSEcCtD
Nabumetone—Fatigue—Triamcinolone—multiple sclerosis	0.000119	0.00105	CcSEcCtD
Nabumetone—MPO—Folate Metabolism—IL6—multiple sclerosis	0.000119	0.00405	CbGpPWpGaD
Nabumetone—Fatigue—Methylprednisolone—multiple sclerosis	0.000119	0.00105	CcSEcCtD
Nabumetone—Loss of consciousness—Prednisone—multiple sclerosis	0.000117	0.00104	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—TNF—multiple sclerosis	0.000117	0.00399	CbGpPWpGaD
Nabumetone—Vomiting—Mitoxantrone—multiple sclerosis	0.000116	0.00103	CcSEcCtD
Nabumetone—Hypertension—Prednisone—multiple sclerosis	0.000115	0.00102	CcSEcCtD
Nabumetone—Rash—Mitoxantrone—multiple sclerosis	0.000115	0.00102	CcSEcCtD
Nabumetone—Dermatitis—Mitoxantrone—multiple sclerosis	0.000115	0.00102	CcSEcCtD
Nabumetone—Chills—Methotrexate—multiple sclerosis	0.000115	0.00102	CcSEcCtD
Nabumetone—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000115	0.00391	CbGpPWpGaD
Nabumetone—Headache—Mitoxantrone—multiple sclerosis	0.000115	0.00101	CcSEcCtD
Nabumetone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000114	0.00101	CcSEcCtD
Nabumetone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000113	0.001	CcSEcCtD
Nabumetone—Anxiety—Prednisone—multiple sclerosis	0.000113	0.001	CcSEcCtD
Nabumetone—Alopecia—Methotrexate—multiple sclerosis	0.000113	0.001	CcSEcCtD
Nabumetone—Insomnia—Dexamethasone—multiple sclerosis	0.000113	0.001	CcSEcCtD
Nabumetone—Insomnia—Betamethasone—multiple sclerosis	0.000113	0.001	CcSEcCtD
Nabumetone—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000113	0.00385	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000113	0.000995	CcSEcCtD
Nabumetone—Paraesthesia—Betamethasone—multiple sclerosis	0.000112	0.000994	CcSEcCtD
Nabumetone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000112	0.000994	CcSEcCtD
Nabumetone—Discomfort—Prednisone—multiple sclerosis	0.000112	0.000993	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—CCR2—multiple sclerosis	0.000111	0.00378	CbGpPWpGaD
Nabumetone—Hypersensitivity—Prednisolone—multiple sclerosis	0.000111	0.000977	CcSEcCtD
Nabumetone—Dyspepsia—Betamethasone—multiple sclerosis	0.00011	0.000974	CcSEcCtD
Nabumetone—Dyspepsia—Dexamethasone—multiple sclerosis	0.00011	0.000974	CcSEcCtD
Nabumetone—Urticaria—Triamcinolone—multiple sclerosis	0.00011	0.000969	CcSEcCtD
Nabumetone—Urticaria—Methylprednisolone—multiple sclerosis	0.000109	0.000967	CcSEcCtD
Nabumetone—Body temperature increased—Triamcinolone—multiple sclerosis	0.000109	0.000964	CcSEcCtD
Nabumetone—Oedema—Prednisone—multiple sclerosis	0.000109	0.000964	CcSEcCtD
Nabumetone—Anaphylactic shock—Prednisone—multiple sclerosis	0.000109	0.000964	CcSEcCtD
Nabumetone—Abdominal pain—Methylprednisolone—multiple sclerosis	0.000109	0.000962	CcSEcCtD
Nabumetone—Decreased appetite—Betamethasone—multiple sclerosis	0.000109	0.000962	CcSEcCtD
Nabumetone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000109	0.000962	CcSEcCtD
Nabumetone—Nausea—Mitoxantrone—multiple sclerosis	0.000109	0.00096	CcSEcCtD
Nabumetone—Fatigue—Dexamethasone—multiple sclerosis	0.000108	0.000954	CcSEcCtD
Nabumetone—Fatigue—Betamethasone—multiple sclerosis	0.000108	0.000954	CcSEcCtD
Nabumetone—Shock—Prednisone—multiple sclerosis	0.000107	0.000948	CcSEcCtD
Nabumetone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000105	0.000932	CcSEcCtD
Nabumetone—PTGS2—Overview of nanoparticle effects—IL6—multiple sclerosis	0.000105	0.00356	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	0.000104	0.00354	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	0.000104	0.00354	CbGpPWpGaD
Nabumetone—Anorexia—Prednisone—multiple sclerosis	0.000104	0.000919	CcSEcCtD
Nabumetone—Ill-defined disorder—Methotrexate—multiple sclerosis	0.000104	0.000916	CcSEcCtD
Nabumetone—Anaemia—Methotrexate—multiple sclerosis	0.000103	0.000912	CcSEcCtD
Nabumetone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000103	0.000912	CcSEcCtD
Nabumetone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000103	0.000912	CcSEcCtD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000102	0.00349	CbGpPWpGaD
Nabumetone—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000102	0.00349	CbGpPWpGaD
Nabumetone—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000102	0.000905	CcSEcCtD
Nabumetone—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000102	0.000905	CcSEcCtD
Nabumetone—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000102	0.000899	CcSEcCtD
Nabumetone—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000101	0.000897	CcSEcCtD
Nabumetone—Malaise—Methotrexate—multiple sclerosis	0.000101	0.00089	CcSEcCtD
Nabumetone—Vertigo—Methotrexate—multiple sclerosis	0.0001	0.000887	CcSEcCtD
Nabumetone—Leukopenia—Methotrexate—multiple sclerosis	9.99e-05	0.000884	CcSEcCtD
Nabumetone—Urticaria—Dexamethasone—multiple sclerosis	9.94e-05	0.000879	CcSEcCtD
Nabumetone—Urticaria—Betamethasone—multiple sclerosis	9.94e-05	0.000879	CcSEcCtD
Nabumetone—Dizziness—Prednisolone—multiple sclerosis	9.92e-05	0.000877	CcSEcCtD
Nabumetone—Asthenia—Triamcinolone—multiple sclerosis	9.9e-05	0.000875	CcSEcCtD
Nabumetone—Abdominal pain—Dexamethasone—multiple sclerosis	9.89e-05	0.000875	CcSEcCtD
Nabumetone—Body temperature increased—Dexamethasone—multiple sclerosis	9.89e-05	0.000875	CcSEcCtD
Nabumetone—Abdominal pain—Betamethasone—multiple sclerosis	9.89e-05	0.000875	CcSEcCtD
Nabumetone—Body temperature increased—Betamethasone—multiple sclerosis	9.89e-05	0.000875	CcSEcCtD
Nabumetone—Asthenia—Methylprednisolone—multiple sclerosis	9.87e-05	0.000873	CcSEcCtD
Nabumetone—Insomnia—Prednisone—multiple sclerosis	9.86e-05	0.000872	CcSEcCtD
Nabumetone—PTGS1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	9.79e-05	0.00334	CbGpPWpGaD
Nabumetone—Paraesthesia—Prednisone—multiple sclerosis	9.79e-05	0.000866	CcSEcCtD
Nabumetone—Pruritus—Triamcinolone—multiple sclerosis	9.76e-05	0.000863	CcSEcCtD
Nabumetone—Cough—Methotrexate—multiple sclerosis	9.74e-05	0.000861	CcSEcCtD
Nabumetone—Pruritus—Methylprednisolone—multiple sclerosis	9.74e-05	0.000861	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—ICAM1—multiple sclerosis	9.72e-05	0.00331	CbGpPWpGaD
Nabumetone—Dyspepsia—Prednisone—multiple sclerosis	9.59e-05	0.000849	CcSEcCtD
Nabumetone—Decreased appetite—Prednisone—multiple sclerosis	9.47e-05	0.000838	CcSEcCtD
Nabumetone—Rash—Prednisolone—multiple sclerosis	9.46e-05	0.000836	CcSEcCtD
Nabumetone—Dermatitis—Prednisolone—multiple sclerosis	9.45e-05	0.000836	CcSEcCtD
Nabumetone—MPO—Selenium Micronutrient Network—IL6—multiple sclerosis	9.44e-05	0.00322	CbGpPWpGaD
Nabumetone—Diarrhoea—Methylprednisolone—multiple sclerosis	9.42e-05	0.000833	CcSEcCtD
Nabumetone—Fatigue—Prednisone—multiple sclerosis	9.4e-05	0.000831	CcSEcCtD
Nabumetone—Headache—Prednisolone—multiple sclerosis	9.4e-05	0.000831	CcSEcCtD
Nabumetone—Discomfort—Methotrexate—multiple sclerosis	9.39e-05	0.00083	CcSEcCtD
Nabumetone—Constipation—Prednisone—multiple sclerosis	9.32e-05	0.000824	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IFNG—multiple sclerosis	9.23e-05	0.00315	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CXCL10—multiple sclerosis	9.21e-05	0.00314	CbGpPWpGaD
Nabumetone—Confusional state—Methotrexate—multiple sclerosis	9.18e-05	0.000812	CcSEcCtD
Nabumetone—Dizziness—Triamcinolone—multiple sclerosis	9.12e-05	0.000807	CcSEcCtD
Nabumetone—Anaphylactic shock—Methotrexate—multiple sclerosis	9.11e-05	0.000806	CcSEcCtD
Nabumetone—Dizziness—Methylprednisolone—multiple sclerosis	9.1e-05	0.000805	CcSEcCtD
Nabumetone—Feeling abnormal—Prednisone—multiple sclerosis	8.98e-05	0.000794	CcSEcCtD
Nabumetone—Asthenia—Betamethasone—multiple sclerosis	8.98e-05	0.000794	CcSEcCtD
Nabumetone—Asthenia—Dexamethasone—multiple sclerosis	8.98e-05	0.000794	CcSEcCtD
Nabumetone—Thrombocytopenia—Methotrexate—multiple sclerosis	8.92e-05	0.000789	CcSEcCtD
Nabumetone—Gastrointestinal pain—Prednisone—multiple sclerosis	8.91e-05	0.000788	CcSEcCtD
Nabumetone—Nausea—Prednisolone—multiple sclerosis	8.91e-05	0.000788	CcSEcCtD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	8.88e-05	0.00303	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	8.88e-05	0.00303	CbGpPWpGaD
Nabumetone—Pruritus—Betamethasone—multiple sclerosis	8.85e-05	0.000783	CcSEcCtD
Nabumetone—Pruritus—Dexamethasone—multiple sclerosis	8.85e-05	0.000783	CcSEcCtD
Nabumetone—Hyperhidrosis—Methotrexate—multiple sclerosis	8.81e-05	0.000779	CcSEcCtD
Nabumetone—Vomiting—Triamcinolone—multiple sclerosis	8.77e-05	0.000776	CcSEcCtD
Nabumetone—Vomiting—Methylprednisolone—multiple sclerosis	8.75e-05	0.000774	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—CCL2—multiple sclerosis	8.7e-05	0.00297	CbGpPWpGaD
Nabumetone—Rash—Triamcinolone—multiple sclerosis	8.7e-05	0.000769	CcSEcCtD
Nabumetone—Dermatitis—Triamcinolone—multiple sclerosis	8.69e-05	0.000768	CcSEcCtD
Nabumetone—Anorexia—Methotrexate—multiple sclerosis	8.68e-05	0.000768	CcSEcCtD
Nabumetone—Rash—Methylprednisolone—multiple sclerosis	8.68e-05	0.000767	CcSEcCtD
Nabumetone—Dermatitis—Methylprednisolone—multiple sclerosis	8.67e-05	0.000767	CcSEcCtD
Nabumetone—Urticaria—Prednisone—multiple sclerosis	8.66e-05	0.000766	CcSEcCtD
Nabumetone—Headache—Triamcinolone—multiple sclerosis	8.64e-05	0.000764	CcSEcCtD
Nabumetone—Headache—Methylprednisolone—multiple sclerosis	8.62e-05	0.000763	CcSEcCtD
Nabumetone—Abdominal pain—Prednisone—multiple sclerosis	8.62e-05	0.000762	CcSEcCtD
Nabumetone—Body temperature increased—Prednisone—multiple sclerosis	8.62e-05	0.000762	CcSEcCtD
Nabumetone—Diarrhoea—Dexamethasone—multiple sclerosis	8.56e-05	0.000757	CcSEcCtD
Nabumetone—Diarrhoea—Betamethasone—multiple sclerosis	8.56e-05	0.000757	CcSEcCtD
Nabumetone—Dizziness—Dexamethasone—multiple sclerosis	8.28e-05	0.000732	CcSEcCtD
Nabumetone—Dizziness—Betamethasone—multiple sclerosis	8.28e-05	0.000732	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—BDNF—multiple sclerosis	8.27e-05	0.00282	CbGpPWpGaD
Nabumetone—Insomnia—Methotrexate—multiple sclerosis	8.24e-05	0.000729	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—IL2—multiple sclerosis	8.2e-05	0.0028	CbGpPWpGaD
Nabumetone—Nausea—Triamcinolone—multiple sclerosis	8.19e-05	0.000725	CcSEcCtD
Nabumetone—Paraesthesia—Methotrexate—multiple sclerosis	8.18e-05	0.000723	CcSEcCtD
Nabumetone—Nausea—Methylprednisolone—multiple sclerosis	8.17e-05	0.000723	CcSEcCtD
Nabumetone—Dyspnoea—Methotrexate—multiple sclerosis	8.12e-05	0.000718	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—ALB—multiple sclerosis	8.11e-05	0.00276	CbGpPWpGaD
Nabumetone—Somnolence—Methotrexate—multiple sclerosis	8.1e-05	0.000716	CcSEcCtD
Nabumetone—Hypersensitivity—Prednisone—multiple sclerosis	8.03e-05	0.00071	CcSEcCtD
Nabumetone—Dyspepsia—Methotrexate—multiple sclerosis	8.02e-05	0.000709	CcSEcCtD
Nabumetone—Vomiting—Betamethasone—multiple sclerosis	7.96e-05	0.000704	CcSEcCtD
Nabumetone—Vomiting—Dexamethasone—multiple sclerosis	7.96e-05	0.000704	CcSEcCtD
Nabumetone—Decreased appetite—Methotrexate—multiple sclerosis	7.92e-05	0.0007	CcSEcCtD
Nabumetone—Rash—Betamethasone—multiple sclerosis	7.89e-05	0.000698	CcSEcCtD
Nabumetone—Rash—Dexamethasone—multiple sclerosis	7.89e-05	0.000698	CcSEcCtD
Nabumetone—Dermatitis—Betamethasone—multiple sclerosis	7.88e-05	0.000697	CcSEcCtD
Nabumetone—Dermatitis—Dexamethasone—multiple sclerosis	7.88e-05	0.000697	CcSEcCtD
Nabumetone—Fatigue—Methotrexate—multiple sclerosis	7.85e-05	0.000695	CcSEcCtD
Nabumetone—Headache—Dexamethasone—multiple sclerosis	7.84e-05	0.000693	CcSEcCtD
Nabumetone—Headache—Betamethasone—multiple sclerosis	7.84e-05	0.000693	CcSEcCtD
Nabumetone—Asthenia—Prednisone—multiple sclerosis	7.82e-05	0.000692	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—ICAM1—multiple sclerosis	7.72e-05	0.00263	CbGpPWpGaD
Nabumetone—Pruritus—Prednisone—multiple sclerosis	7.71e-05	0.000682	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—IL4—multiple sclerosis	7.68e-05	0.00262	CbGpPWpGaD
Nabumetone—Feeling abnormal—Methotrexate—multiple sclerosis	7.51e-05	0.000664	CcSEcCtD
Nabumetone—Diarrhoea—Prednisone—multiple sclerosis	7.46e-05	0.00066	CcSEcCtD
Nabumetone—Gastrointestinal pain—Methotrexate—multiple sclerosis	7.45e-05	0.000659	CcSEcCtD
Nabumetone—Nausea—Betamethasone—multiple sclerosis	7.43e-05	0.000657	CcSEcCtD
Nabumetone—Nausea—Dexamethasone—multiple sclerosis	7.43e-05	0.000657	CcSEcCtD
Nabumetone—PTGS1—Selenium Micronutrient Network—IFNG—multiple sclerosis	7.4e-05	0.00252	CbGpPWpGaD
Nabumetone—Urticaria—Methotrexate—multiple sclerosis	7.24e-05	0.00064	CcSEcCtD
Nabumetone—Dizziness—Prednisone—multiple sclerosis	7.21e-05	0.000637	CcSEcCtD
Nabumetone—Body temperature increased—Methotrexate—multiple sclerosis	7.2e-05	0.000637	CcSEcCtD
Nabumetone—Abdominal pain—Methotrexate—multiple sclerosis	7.2e-05	0.000637	CcSEcCtD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.05e-05	0.0024	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.05e-05	0.0024	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	7.01e-05	0.00239	CbGpPWpGaD
Nabumetone—Vomiting—Prednisone—multiple sclerosis	6.93e-05	0.000613	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—CCL2—multiple sclerosis	6.91e-05	0.00235	CbGpPWpGaD
Nabumetone—Rash—Prednisone—multiple sclerosis	6.87e-05	0.000608	CcSEcCtD
Nabumetone—Dermatitis—Prednisone—multiple sclerosis	6.87e-05	0.000607	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	6.86e-05	0.00234	CbGpPWpGaD
Nabumetone—Headache—Prednisone—multiple sclerosis	6.83e-05	0.000604	CcSEcCtD
Nabumetone—Hypersensitivity—Methotrexate—multiple sclerosis	6.71e-05	0.000594	CcSEcCtD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	6.71e-05	0.00229	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL1B—multiple sclerosis	6.6e-05	0.00225	CbGpPWpGaD
Nabumetone—Asthenia—Methotrexate—multiple sclerosis	6.54e-05	0.000578	CcSEcCtD
Nabumetone—Nausea—Prednisone—multiple sclerosis	6.47e-05	0.000573	CcSEcCtD
Nabumetone—Pruritus—Methotrexate—multiple sclerosis	6.44e-05	0.00057	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—ALB—multiple sclerosis	6.44e-05	0.00219	CbGpPWpGaD
Nabumetone—PTGS2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	6.39e-05	0.00218	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TLR4—multiple sclerosis	6.37e-05	0.00217	CbGpPWpGaD
Nabumetone—Diarrhoea—Methotrexate—multiple sclerosis	6.23e-05	0.000551	CcSEcCtD
Nabumetone—PTGS2—Spinal Cord Injury—ICAM1—multiple sclerosis	6.1e-05	0.00208	CbGpPWpGaD
Nabumetone—Dizziness—Methotrexate—multiple sclerosis	6.02e-05	0.000533	CcSEcCtD
Nabumetone—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—multiple sclerosis	5.98e-05	0.00204	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—CD4—multiple sclerosis	5.89e-05	0.00201	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IFNG—multiple sclerosis	5.87e-05	0.002	CbGpPWpGaD
Nabumetone—Vomiting—Methotrexate—multiple sclerosis	5.79e-05	0.000512	CcSEcCtD
Nabumetone—Rash—Methotrexate—multiple sclerosis	5.74e-05	0.000508	CcSEcCtD
Nabumetone—Dermatitis—Methotrexate—multiple sclerosis	5.74e-05	0.000507	CcSEcCtD
Nabumetone—Headache—Methotrexate—multiple sclerosis	5.71e-05	0.000505	CcSEcCtD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	5.63e-05	0.00192	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—SRM—multiple sclerosis	5.61e-05	0.00191	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	5.58e-05	0.0019	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—CCL2—multiple sclerosis	5.46e-05	0.00186	CbGpPWpGaD
Nabumetone—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.43e-05	0.00185	CbGpPWpGaD
Nabumetone—Nausea—Methotrexate—multiple sclerosis	5.41e-05	0.000479	CcSEcCtD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL1B—multiple sclerosis	5.24e-05	0.00179	CbGpPWpGaD
Nabumetone—PTGS1—Biological oxidations—POMC—multiple sclerosis	5.2e-05	0.00177	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	4.98e-05	0.0017	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	4.96e-05	0.00169	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	4.82e-05	0.00164	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—TNF—multiple sclerosis	4.79e-05	0.00163	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IFNG—multiple sclerosis	4.64e-05	0.00158	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—SRM—multiple sclerosis	4.46e-05	0.00152	CbGpPWpGaD
Nabumetone—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.4e-05	0.0015	CbGpPWpGaD
Nabumetone—PTGS2—C-MYB transcription factor network—MYC—multiple sclerosis	4.24e-05	0.00144	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL1B—multiple sclerosis	4.14e-05	0.00141	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL2—multiple sclerosis	4.13e-05	0.00141	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	3.99e-05	0.00136	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	3.99e-05	0.00136	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP27B1—multiple sclerosis	3.96e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—CYP24A1—multiple sclerosis	3.96e-05	0.00135	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MMP9—multiple sclerosis	3.91e-05	0.00133	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	3.88e-05	0.00132	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	3.87e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.87e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS1—Selenium Micronutrient Network—IL6—multiple sclerosis	3.86e-05	0.00132	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—TNF—multiple sclerosis	3.8e-05	0.0013	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.8e-05	0.00129	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—GPC5—multiple sclerosis	3.62e-05	0.00123	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.61e-05	0.00123	CbGpPWpGaD
Nabumetone—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.61e-05	0.00123	CbGpPWpGaD
Nabumetone—PTGS2—Disease—GPC5—multiple sclerosis	3.43e-05	0.00117	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MYC—multiple sclerosis	3.23e-05	0.0011	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TGFB1—multiple sclerosis	3.22e-05	0.0011	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—MAPK1—multiple sclerosis	3.16e-05	0.00108	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP27B1—multiple sclerosis	3.14e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—CYP24A1—multiple sclerosis	3.14e-05	0.00107	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.07e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Selenium Micronutrient Network—IL6—multiple sclerosis	3.07e-05	0.00105	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—TNF—multiple sclerosis	3.01e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—RRM1—multiple sclerosis	3e-05	0.00102	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—GPC5—multiple sclerosis	2.87e-05	0.000979	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—SRM—multiple sclerosis	2.52e-05	0.00086	CbGpPWpGaD
Nabumetone—PTGS2—Spinal Cord Injury—IL6—multiple sclerosis	2.43e-05	0.000827	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—RRM1—multiple sclerosis	2.38e-05	0.000811	CbGpPWpGaD
Nabumetone—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.34e-05	0.000797	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.33e-05	0.000793	CbGpPWpGaD
Nabumetone—PTGS2—Disease—RPL5—multiple sclerosis	2.23e-05	0.00076	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	2.2e-05	0.000748	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	2.19e-05	0.000746	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	2.15e-05	0.000732	CbGpPWpGaD
Nabumetone—PTGS2—Disease—SLC11A1—multiple sclerosis	2.14e-05	0.000728	CbGpPWpGaD
Nabumetone—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.05e-05	0.000697	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2e-05	0.000681	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.85e-05	0.000629	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.82e-05	0.000621	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.78e-05	0.000606	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.78e-05	0.000606	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.74e-05	0.000592	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—BCHE—multiple sclerosis	1.72e-05	0.000587	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD28—multiple sclerosis	1.71e-05	0.000581	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.63e-05	0.000554	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.59e-05	0.000541	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.45e-05	0.000493	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—BCHE—multiple sclerosis	1.37e-05	0.000466	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.35e-05	0.000459	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD86—multiple sclerosis	1.22e-05	0.000415	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CCR5—multiple sclerosis	1.08e-05	0.000368	CbGpPWpGaD
Nabumetone—PTGS2—Disease—HLA-A—multiple sclerosis	1.05e-05	0.000358	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.04e-05	0.000356	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—APOE—multiple sclerosis	1.04e-05	0.000353	CbGpPWpGaD
Nabumetone—PTGS2—Disease—APOE—multiple sclerosis	9.82e-06	0.000335	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	8.97e-06	0.000306	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—POMC—multiple sclerosis	8.9e-06	0.000303	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD80—multiple sclerosis	8.88e-06	0.000303	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—APOE—multiple sclerosis	8.22e-06	0.00028	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.18e-06	0.000279	CbGpPWpGaD
Nabumetone—PTGS1—Metabolism—ALB—multiple sclerosis	8.11e-06	0.000276	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—BCHE—multiple sclerosis	7.73e-06	0.000264	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TYK2—multiple sclerosis	7.49e-06	0.000255	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—POMC—multiple sclerosis	7.06e-06	0.000241	CbGpPWpGaD
Nabumetone—PTGS2—Disease—CD4—multiple sclerosis	6.78e-06	0.000231	CbGpPWpGaD
Nabumetone—PTGS2—Metabolism—ALB—multiple sclerosis	6.44e-06	0.000219	CbGpPWpGaD
Nabumetone—PTGS2—Disease—STAT3—multiple sclerosis	5.25e-06	0.000179	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MYC—multiple sclerosis	4.88e-06	0.000166	CbGpPWpGaD
Nabumetone—PTGS2—Disease—TGFB1—multiple sclerosis	4.86e-06	0.000166	CbGpPWpGaD
Nabumetone—PTGS2—Disease—MAPK1—multiple sclerosis	4.77e-06	0.000163	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—APOE—multiple sclerosis	4.65e-06	0.000159	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—POMC—multiple sclerosis	4e-06	0.000136	CbGpPWpGaD
Nabumetone—PTGS2—Disease—IL6—multiple sclerosis	3.66e-06	0.000125	CbGpPWpGaD
Nabumetone—CYP1A2—Metabolism—ALB—multiple sclerosis	3.64e-06	0.000124	CbGpPWpGaD
